RBC Capital Maintains Outperform on Legend Biotech, Raises Price Target to $86
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Leonid Timashev maintains an Outperform rating on Legend Biotech (NASDAQ:LEGN) and raises the price target from $85 to $86.
May 14, 2024 | 3:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital's updated Outperform rating and increased price target from $85 to $86 for Legend Biotech may positively influence investor sentiment and potentially lead to a short-term uptick in LEGN's stock price.
Analyst ratings and price target adjustments are significant indicators for investors, often influencing stock prices. The increase in LEGN's price target by a reputable analyst like Leonid Timashev signals confidence in the company's future performance, likely encouraging positive investor sentiment and potentially leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100